LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.25), Zacks reports. The firm had revenue of $32.20 million during the quarter, compared to analysts’ expectations of $23.31 million.
LogicBio Therapeutics Price Performance
Shares of LOGC opened at $14.00 on Tuesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.87 and a quick ratio of 1.24. The company’s fifty day moving average price is $14.79 and its 200-day moving average price is $10.37. LogicBio Therapeutics has a 1-year low of $7.05 and a 1-year high of $15.60. The firm has a market capitalization of $640.22 million, a PE ratio of -19.18 and a beta of 2.11.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.
LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.
Featured Stories
- Five stocks we like better than LogicBio Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
